Position in BLTE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,704,732
New position
Shares Held
10,692
first reported quarter
Ownership
0.027%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Blackstone Inc. holds $185,974,784 across 43 Biotechnology names. BLTE ranks #22 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AUTL |
Autolus Therapeutics plc
|
20,485,611 | $28,270,143 | |
| 2 | SYRE |
Spyre Therapeutics, Inc.
|
292,847 | $14,771,202 | |
| 3 | DMRA |
Damora Therapeutics, Inc.
|
503,522 | $13,041,219 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
|
231,282 | $12,193,187 | |
| 5 | TARA |
Protara Therapeutics, Inc.
|
2,265,514 | $11,803,327 | |
| 6 | ALXO |
Alx Oncology Holdings Inc
|
5,826,544 | $11,682,220 | |
| 7 | XFOR |
X4 Pharmaceuticals, Inc
|
2,681,922 | $11,076,337 | |
| 8 | IKT |
Inhibikase Therapeutics, Inc.
|
5,938,276 | $9,976,303 |
All Filings in BLTE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,704,732 | 10,692 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||